The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Walter Fiedler

University Medical Center Hamburg-Eppendorf

Hubertus Wald University Cancer Center

20246 Hamburg



Name/email consistency: high



  • University Medical Center Hamburg-Eppendorf, Hubertus Wald University Cancer Center, 20246 Hamburg, Germany. 2011
  • Department of Oncology, Hematology, BMT With Section Pneumology, Hubertus Wald Tumorzentrum, Germany. 2011
  • Department of Oncology, Hematology, BMT with section Pneumology Hubertus Wald Tumorzentrum - University Cancer Center Hamburg University Medical Center Hamburg Eppendorf 20246 Hamburg, Germany. 2010
  • Department of Oncology/Hematology, University Hospital Eppendorf, Hamburg, Germany. 2001 - 2006


  1. Clinical experience with antiangiogenic therapy in leukemia. Wellbrock, J., Fiedler, W. Curr. Cancer. Drug. Targets (2011) [Pubmed]
  2. Phase I trial of SU14813 in patients with advanced solid malignancies. Fiedler, W., Giaccone, G., Lasch, P., van der Horst, I., Brega, N., Courtney, R., Abbattista, A., Shalinsky, D.R., Bokemeyer, C., Boven, E. Ann. Oncol. (2011) [Pubmed]
  3. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Fiedler, W., Mesters, R., Heuser, M., Ehninger, G., Berdel, W.E., Zirrgiebel, U., Robertson, J.D., Puchalski, T.A., Collins, B., Jürgensmeier, J.M., Serve, H. Leuk. Res. (2010) [Pubmed]
  4. A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. Fiedler, W., Tchen, N., Bloch, J., Fargeot, P., Sorio, R., Vermorken, J.B., Collette, L., Lacombe, D., Twelves, C. Eur. J. Cancer (2006) [Pubmed]
  5. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Fiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O.G., O'Farrell, A.M., Bello, C.L., Allred, R., Manning, W.C., Cherrington, J.M., Louie, S.G., Hong, W., Brega, N.M., Massimini, G., Scigalla, P., Berdel, W.E., Hossfeld, D.K. Blood (2005) [Pubmed]
  6. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Duhrsen, U., Flasshove, M., Ottmann, O.G., Jung, W., Cavalli, F., Kuse, R., Thomalla, J., Serve, H., O'Farrell, A.M., Jacobs, M., Brega, N.M., Scigalla, P., Hossfeld, D.K., Berdel, W.E. Blood (2003) [Pubmed]
  7. A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer. Fiedler, W., Krüger, W., Laack, E., Mende, T., Vohwinkel, G., Hossfeld, D.K. Oncol. Rep. (2001) [Pubmed]
WikiGenes - Universities